Lorlatinib

洛拉替尼

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameLorlatinib
Drug Alias NameLorbrena劳拉替尼LorviquaLorbrena博瑞纳 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitors
TargetsAnaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROS
Therapy Area/IndicationsLiver DiseasesCarcinoma, Non-Small-Cell LungNeuroblastoma +[5] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryJapan
Original Approved Date2018/09/21
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPeople'S Liberation Army Air Force Military Medical UniversityUniversity Of Milano BicoccaPfizer Inc +[9] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterCstone Pharmaceuticals (Suzhou) Co Ltd
Active IndicationsLiver DiseasesCarcinoma, Non-Small-Cell LungNeuroblastoma +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01ED05
Related LinksWikipediaDrugBankKEGG